Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review.

ABSTRACT

The introduction in recent years of biologic medicines has greatly changed the treatment of psoriasis and psoriatic arthropathy (PsA). These drugs have been effective in the treatment of these chronic, physically weakening disorders, offering good efficacy and a safety profile that differs from those of all other systemic therapies and medications available to date. Different studies have assessed the efficacy and safety of etanercept in the treatment of psoriasis and PsA. Etanercept therapy for up to 144 weeks in psoriasis has shown maintenance of efficacy over time, recapture of initial clinical responses in patients who interrupted their etanercept therapy and were re-treated, an increased percentage of clinical responses in medium-dose non-responding patients who switched to higher dosages, good responses on quality-of-life tests, and an adverse event-adjusted rate similar to placebo. In PsA, etanercept therapy for up to 96 weeks was associated with inhibition of radiologic progression of the disease in addition to maintenance of efficacy over time and good responses on quality-of-life tests. In studies of patients with psoriasis, the adverse effects of etanercept were mostly mild, did not require discontinuation of treatment, and were not associated with cumulative toxicity over time. However, safety concerns about etanercept therapy are well known, and include injection-site reactions, infections, congestive heart failure, demyelinating diseases, lupus-like syndromes, and neoplasms. There are no data about any new safety concerns when etanercept is combined with systemic traditional therapies, although use of this therapy has been reported in only a small number of patients to date.Non-neutralizing anti-etanercept antibodies are not related to a decreased response to therapy and neutralizing antibodies have not been described to date. Treatment of patients infected with hepatitis C virus or HIV does not increase viral load in either case, affect liver function tests, or increase the risk of infections. To date, the available data suggest that use of etanercept during pregnancy or in breast-feeding women should be avoided. Children and the elderly may be treated with similar efficacy and safety profiles as have been observed in adults. Non-live vaccines can be administered to patients taking etanercept. Because of its long-term efficacy and safety, etanercept is likely to become a treatment option for consideration in the long-term management of patients with psoriasis and PsA.